Clinicopathological characteristics, prognosis, and chemosensitivity in patients with metastatic upper tract urothelial carcinoma

被引:13
作者
Li, Xu [1 ,2 ]
Li, Siming [3 ]
Chi, Zhihong [3 ]
Cui, Chuanliang [3 ]
Si, Lu [3 ]
Yan, Xieqiao [3 ]
Mao, Lili [3 ]
Lian, Bin [3 ]
Tang, Bixia [3 ]
Wang, Xuan [3 ]
Bai, Xue [3 ]
Zhou, Li [3 ]
Kong, Yan [3 ]
Dai, Jie [3 ]
Guo, Jun [3 ]
Sheng, Xinan [3 ]
机构
[1] Chinese Acad Med Sci, Natl Ctr Gerontol, Beijing Hosp, Dept Oncol, Beijing, Peoples R China
[2] Chinese Acad Med Sci, Inst Geriatr Med, Beijing, Peoples R China
[3] Peking Univ Canc Hosp & Inst, Dept Renal Canc & Melanoma, Minist Educ Beijing, Key Lab Carcinogenesis & Translat Res, Beijing, Peoples R China
关键词
Upper tract urothelial carcinoma; Urothelial bladder carcinoma; Metastatic pattern; Chemosensitivity; Prognosis; TRANSITIONAL-CELL-CARCINOMA; UPPER URINARY-TRACT; BLADDER; THERAPY; CHEMOTHERAPY; MULTICENTER; PATTERNS; BEHAVIOR; CANCER;
D O I
10.1016/j.urolonc.2020.06.010
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To investigate the clinical characteristics, chemosensitivity, and outcome of metastatic upper tract urothelial carcinoma (UTUC). Patients and Methods: Records of patients with metastatic UTUC since January 2005 were retrieved from a database that included clinical and survival data. Statistical analyses including survival and multivariate analyses of factors were respectively performed by the Kaplan-Meier method and Cox proportional hazard model. Results: A total of 250 consecutive UTUC cases were evaluated. There were 56 patients (22.4%) with initially diagnosed stage IV disease. The most common metastatic sites were lung (39.6%), distant lymph nodes (39.2%), bone (19.6%), liver (18.0%), and adrenal gland (7.2%), respectively, and the local recurrence rate was 10.4%. Two hundred thirteen patients received first-line chemotherapy. The overall response rate was only 28.7% and the median progression-free survival time was only 5.0 months. The overall survival time of the cohort was 18.0 months. Multivariate analyses showed that initially diagnosed stage IV disease, number of metastatic organs >= 3, no response to chemotherapy and cycles of chemotherapy <= 2 were adverse prognosticators for overall survival. Conclusion: UTUC presented to be more prone to metastasize than locally recur and thought to have low chemosensitivity. Stage IV disease at initial diagnosis, number of metastatic organs, response and cycles of chemotherapy were independent prognosticators for metastatic UTUC. (C) 2020 Elsevier Inc. All rights reserved.
引用
收藏
页码:75.e1 / 75.e8
页数:8
相关论文
共 30 条
[1]  
[Anonymous], 2015, UROL ONCOL
[2]   Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study [J].
Apolo, Andrea B. ;
Infante, Jeffrey R. ;
Balmanoukian, Ani ;
Patel, Manish R. ;
Wang, Ding ;
Kelly, Karen ;
Mega, Anthony E. ;
Britten, Carolyn D. ;
Ravaud, Alain ;
Mita, Alain C. ;
Safran, Howard ;
Stinchcombe, Thomas E. ;
Srdanov, Marko ;
Gelb, Arnold B. ;
Schlichting, Michael ;
Chin, Kevin ;
Gulley, James L. .
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (19) :2117-+
[3]   Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma [J].
Bellmunt, J. ;
de Wit, R. ;
Vaughn, D. J. ;
Fradet, Y. ;
Lee, J. -L. ;
Fong, L. ;
Vogelzang, N. J. ;
Climent, M. A. ;
Petrylak, D. P. ;
Choueiri, T. K. ;
Necchi, A. ;
Gerritsen, W. ;
Gurney, H. ;
Quinn, D. I. ;
Culine, S. ;
Sternberg, C. N. ;
Mai, Y. ;
Poehlein, C. H. ;
Perini, R. F. ;
Bajorin, D. F. .
NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (11) :1015-1026
[4]   Randomized Phase III Study Comparing Paclitaxel/Cisplatin/Gemcitabine and Gemcitabine/Cisplatin in Patients With Locally Advanced or Metastatic Urothelial Cancer Without Prior Systemic Therapy: EORTC Intergroup Study 30987 [J].
Bellmunt, Joaquim ;
von der Maase, Hans ;
Mead, Graham M. ;
Skoneczna, Iwona ;
De Santis, Maria ;
Daugaard, Gedske ;
Boehle, Andreas ;
Chevreau, Christine ;
Paz-Ares, Luis ;
Laufman, Leslie R. ;
Winquist, Eric ;
Raghavan, Derek ;
Marreaud, Sandrine ;
Collette, Sandra ;
Sylvester, Richard ;
de Wit, Ronald .
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (10) :1107-1113
[5]   Prognostic Factors in Patients With Advanced Transitional Cell Carcinoma of the Urothelial Tract Experiencing Treatment Failure With Platinum-Containing Regimens [J].
Bellmunt, Joaquim ;
Choueiri, Toni K. ;
Fougeray, Ronan ;
Schutz, Fabio A. B. ;
Salhi, Yacine ;
Winquist, Eric ;
Culine, Stephane ;
von der Maase, Hans ;
Vaughn, David J. ;
Rosenberg, Jonathan E. .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (11) :1850-1855
[6]   Results of POUT: A phase III randomised trial of perioperative chemotherapy versus surveillance in upper tract urothelial cancer (UTUC). [J].
Birtle, Alison Jane ;
Chester, John David ;
Jones, Robert Jones ;
Johnson, Mark ;
Hill, Michaela ;
Bryan, Richard T. ;
Catto, James ;
Donovan, Jenny ;
French, Ann ;
Harris, Chris ;
Keeley, Francis ;
Kockelbergh, Roger ;
Powles, Thomas ;
Todd, Rachel ;
Tregellas, Lucy ;
Wilson, Caroline ;
Winterbottom, Andrew ;
Lewis, Rebecca ;
Hall, Emma .
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
[7]   Behavior of urothelial carcinoma with respect to anatomical location [J].
Catto, J. W. F. ;
Yates, D. R. ;
Rehman, I. ;
Azzouzi, A. R. ;
Patterson, J. ;
Sibony, M. ;
Cussenot, O. ;
Hamdy, F. C. .
JOURNAL OF UROLOGY, 2007, 177 (05) :1715-1720
[8]   Impact of gender on bladder cancer incidence, staging, and prognosis [J].
Fajkovic, Harun ;
Halpern, Joshua A. ;
Cha, Eugene K. ;
Bahadori, Atessa ;
Chromecki, Thomas F. ;
Karakiewicz, Pierre I. ;
Breinl, Eckart ;
Merseburger, Axel S. ;
Shariat, Shahrokh F. .
WORLD JOURNAL OF UROLOGY, 2011, 29 (04) :457-463
[9]   Urothelial Carcinoma of the Bladder and the Upper Tract: Disparate Twins [J].
Green, David A. ;
Rink, Michael ;
Xylinas, Evanguelos ;
Matin, Surena F. ;
Stenzl, Arnulf ;
Roupret, Morgan ;
Karakiewicz, Pierre I. ;
Scherr, Douglas S. ;
Shariat, Shahrokh F. .
JOURNAL OF UROLOGY, 2013, 189 (04) :1214-1221
[10]   Do metastatic upper tract urothelial carcinoma and bladder carcinoma have similar clinical responses to systemic chemotherapy? A Japanese multi-institutional experience [J].
Kikuchi, Eiji ;
Miyazaki, Jun ;
Yuge, Kazuyuki ;
Hagiwara, Masayuki ;
Ichioka, Daishi ;
Inoue, Takamitsu ;
Kageyama, Susumu ;
Sugimoto, Mikio ;
Mitsuzuka, Koji ;
Matsui, Yoshiyuki ;
Yamamoto, Shingo ;
Kinoshita, Hidefumi ;
Wakeda, Hironobu ;
Hanai, Kazuya ;
Nishiyama, Hiroyuki .
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2016, 46 (02) :163-169